Back to Explorer

Points to Consider for Cervical Cytology Devices

FinalCenter for Devices and Radiological Health07/25/1994
Good Guidance Practicessoftware validationgood laboratory practicesData integrityGood Manufacturing PracticesPost-market studies

Description

This points-to-considerdocumentsupplements existing FDA guidance for premarket submission of in vitro diagnostic devices for approval or clearance. The information requested is intended to be comprehensive but may not be all inclusive. The emphasis is on FDA's particular concerns in the review of cytology devices for gynecologic specimens.

Key Topics

Terms and concepts identified from this document

Scope & Applicability

Product Classes

3
Cervical Cytology Devices

Subject of the points-to-consider document; Guidance document title and subject of clinical study requirements; The primary subject of the guidance document.; Subject of the guidance document regarding points to consider for regulatory submission.

in vitro diagnostic devices

Devices compared to reference methods or gold standards

Conventional Pap smear

Reference method for cervical cytology

Stakeholders

4
sponsor

responsible for justifying omission of studies

Manufacturer

Entity responsible for submitting NDINs

Cytotechnologist

Professional screening specimens for analysis.; Role responsible for referring slides to the next higher trained observer.

Pathologist

Performs histopathological assessment of biopsies

Regulatory Context

Regulatory Activities

4
premarket submission

Regulatory filing such as a 510(k) or PMA submitted to the FDA.; Submission including ASCA testing results

510(k)

Premarket notification submission type

PMA

Premarket Approval Application

Investigational Device Exemption

A medical device submission type (IDE).

Document Types

4
protocol

Submitted to an existing active IND

work sheet

Original records where data and diagnoses are recorded and must be maintained.

study protocol

Definitions, algorithms, and data elements should be included in the study protocol.

IRB-approved written protocol

Required documentation for using negative archival slides

Attributes

5
Stability

A functional role of sodium in food

workload limit

Evaluation required for all gynecologic cytology devices submitted for FDA approval.

Clinical sensitivity

the biomarker's clinical sensitivity, specificity, and positive and negative predictive values should be well characterized

Clinical specificity

used to inform the choice of a biomarker cutoff

Disease prevalence

Required data for pediatric population estimates

Technical Details

Testing Methods

10
Pap tests

Over 50 million performed each year

Pap test

Conventional methodology used as a baseline for comparison with new devices.

manual microscopy

Used to verify abnormal cells identified by computer-assisted devices.

Colposcopy

technique to detect epithelial disruption and local malignancy

Directed biopsy

Clinical endpoint or surrogate endpoint

Hypothesis testing

Commonly used to address uncertainty in the assessment of a treatment effect; The graph shows each of the hypotheses located at a vertex.

Viral culture

Sampling requirement for specific conditions claimed in intended use.

Nucleotide studies

Sampling requirement for specific conditions claimed in intended use.

Pap smears

Conventional method used as a reference for cervical cytology.

Cervical biopsy

A reference method for accuracy, though less than a gold standard.

Processes

3
Premarketing studies

Studies conducted to detect or analyze conditions before marketing.

sample preparation

In vitro methods for product quality and performance assessments

Differential separation

Processing method for cervical cells from mucus and other materials.

Clinical Concepts

6
ASCUS

Atypical squamous cells of undetermined significance

Atypical squamous cells of undetermined significance

TBS diagnosis category (ASCUS).

High grade squamous intraepithelial lesion

TBS diagnosis category (HGSIL).

LGSIL

Low grade squamous intraepithelial lesion

HGSIL

High grade squamous intraepithelial lesion

AGCUS

Atypical glandular cells of undetermined significance

Identified Hazards

Hazards

1
Hazard analysis

Required for computer controlled medical devices.

Standards & References

External Standards

2
The Bethesda System

Confirmatory test must be performed according to TBS guidelines; Standard for cervical cytology diagnoses (TBS); TBS categories used for screening diagnoses and reporting cervical/vaginal cytological diagnosis.

Bethesda System

System used to categorize cervical diseases and conditions (TBS).

Specifications

3
Accuracy

Define and document a minimum set of metrics (e.g., accuracy)

Precision

Define and document a minimum set of metrics (e.g., precision)

Clinical accuracy

The validation end-point for in vitro diagnostic methods.

Related CFR Sections (3)

See Also (1)

Points to Consider for Cervical Cytology Devices | Guideline Explorer | BioRegHub